Replay available

Compugen (NASDAQ:CGEN) Q1 2021 Earnings Call

Compugen (NASDAQ:CGEN) Q1 2021 earnings call, held 2021-05-13. Watch the replay and read the transcript on 6ix.

Thu, May 13, 2021 at 8:30 AMendedReplay
Compugen (NASDAQ:CGEN) Q1 2021 Earnings Call
Company
Compugen Ltd. (NASDAQ:CGEN)
Period
Q1 2021 earnings call
Date
Thu, May 13, 2021, 8:30 AM ET
Replay
Watch the replay on this page · 59 min
Results news release
Compugen Reports First Quarter 2021 Results · Thu, May 13, 2021

On 6ix: 6ix.com/event/compugen-ltd-cgen-q1-2021-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's first quarter 2021 result conference call. At this time, all participants are in a listen-only mode. An audio webcast of this call is available in the investor section of Compugen's website at www.cgen.com. As a reminder, today's call is being recorded. With us from Compugen are Dr. Anat Cohen-Dayag, Ari Krashen, CFO and COO, and Dr. Henry Attaway, Chief Medical Officer, who will be available for questions at the end of the call. Before we begin, I would like to read the following regarding forward-looking statements.

0:45 During the course of this conference call, the company may make projections or other forward-looking statements regarding future events or future business outlook, our development efforts and their outcome, our discovery platform, anticipated progress, and Timeline for our programs, financial and accounting related matters as well as statements regarding our cash position. We wish to caution you that such statements reflect only on the company's current expectations and that actual events or results may differ materially. You are kindly referred to the risk factors and cautionary language contained in the documents the company filed with the Securities and Exchange Commission, including the company's most recent annual report on Form 20-F, filed on February 25th, 2021. The company undertakes no obligation to update projections or forward-looking statements in the future. I would now turn over the call to Anat.

1:43 Anat?

1:45 Thank you, operator. Good morning and good afternoon, everyone, and welcome to our first quarter 2021 corporate and financial update. We have started 2021 from a strong position building on our timely execution for our 2020 guidance and plans. We believe 2021 is supposed to be an important year for Compugen as we continue our efforts to build a robust clinical pipeline with multiple clinical studies while further deepen the scientific foundation for our differentiated programs. We have developed a comprehensive clinical development program designed to systematically elucidate the role of our internally discovered and wholly owned anti-PVRIG and TGIT assets across settings and combination regimens.

2:46 With steady execution, we have made great progress both clinically and research-wise in understanding the role of the DYNAM-AXIS members, PVRIG and TIGIT, as potentially foundational immunotherapy checkpoint targets. Our work has identified PVRIG and TIGIT as key parallel and complementary inhibitory pathways in the DYNAM-AXIS, which also intersects with the well-established PD-1 pathway. Together, our data suggest that these three inhibitory pathways have different dominance in different tumor types and patients, which means that in order to induce effective anti-tumor responses, certain patient populations may require the blockade of different combinations of these three pathways.

3:46 With this in mind, we have established a science-driven and data-informed and the clinical program, which evaluates different combinations of these axis members across indications that we believe will be most relevant in the clinic. On our last call, we shared data from the combination arm of the Phase I dose escalation study of COM701 in combination with Bristol-Mell-Scripps nivolumab, as well as follow-up data from our monotherapy dose escalation and cohort expansion study. For the combination arm dose escalation, we provided complete data from all five dose levels in the study.

4:38 Our encouraging results showed a disease control rate of approximately 67%, which is a significant accomplishment given the highly refractory, heavily pretreated, and Advanced Disease Patient Population. Equally important are the observed durable responses in multiple patients and across indications which include patients with complete and partial responses with patients on study treatment for almost a year or in some cases for more than a year. An additional meaningful highlight from these updated data relates to the patient with a complete response who prior to being enrolled in our study had disease progression on a checkpoint inhibitor.

5:32 This data suggests the dual blockade of PDR-IG and PD-1 may be key to driving antithrombin immune responses in certain patient populations. These readouts are particularly significant Given our latest announcement of our expanded clinical collaboration with Bristol-Mers Squibb to initiate a Phase 1b dual combination expansive study of COM701 in combination with nivolumab, which is expected to begin in the second quarter of 2021. This study will enroll patients with ovarian, breast, endometrial, and microsatellite-stable colorectal cancer and is an important addition to our clinical strategy expanding the potential reach of this combination regimen while also providing insight towards the contribution of the different components of the denim axis across our ongoing and future COM701 studies and specifically our ongoing triplet study We also shared initial data from our COM701 monotherapy cohort expansion, a safety and tolerability study with a biomarker-informed strategy

7:05 to select tumor types most likely to respond to treatment based on preclinical expression data and clinical results from the dose escalation arm. These indications are endometrial, breast, ovarian, colorectal, and non-small cell and cancer. Enrollment of 20 patients in the study was completed in the fourth quarter of 2022. As of the data cutoff date we presented last quarter, six out of 20 patients had the best response of stable disease across endometrial, non-small cell lung, and ovarian cancer, and two patients with durable antitumor activity continuing on treatment.

7:58 These data, combined with our COM701 dose escalation data, provide signals of antitumor activity in a monotherapy setting in tumor types typically unresponsive to immune checkpoint inhibitors. In addition, some of these single agent signals are durable, including a patient with a confirmed partial response from the dose escalation study on treatment for over one year as of the data cutoff date presented last quarter. It should be noted that these were highly refractory patients who exhausted all treatment options with tumor types that are typically non-responsive to checkpoint inhibitors, including patients with prior progression on these treatments, which together suggest that PVRIG blockade may be an important untapped checkpoint that has the potential of driving anti-tumor immune responses.

9:07 The clinical data across the combination and monotherapy arms leaves us increasingly confident in our prediction that there are certain patient populations which are likely to respond to PVRIG blockers and or PVRIG and PD-1 dual blockade, including those that have progressed on immune checkpoint blockers. Another angle to evaluate the activity of CON701 is the data analysis in progress from the COM701 Monotherapy Cohort Expansion Study that will include correlative assessments based on data from patient samples including cytokines, immune phenotyping, and immunohistochemistry analysis.

10:02 This data that will also be gathered from our dual and triple combination studies will enable us to gain insights relating to COM701 and PVRIG-PVRL2 pathway biology, particularly in indications that are typically not responsive to PD-1 blockade. Our initial assessments of patients' peripheral blood samples suggest that COM701 may enhance immune activation in cancer patients alone or in combination with nivolumab. These results provide for the first time an indication for the potential effect of PVRIG blockade in peripheral blood of cancer patients treated with COM701.

10:58 We are excited to be providing updated data from the COM701 monotherapy and combination with nivolumab studies in our upcoming oral presentation at ASCO on June 7, 2021, and look forward to sharing the data following our oral presentation. We continue to invest in our clinical programs and have expanded our clinical strategy to include multiple clinical studies in order to maintain our leadership position in the evaluation of the DYNAM-AXIS pathway. Moving forward in 2021, we expect to continue to execute across our broad clinical strategy, which includes the ongoing triplet study of COM701 with nivolumab and Bristol-Merce-Quiggs TG inhibitor, the initiation of the doublet expansion study of COM701 with nivolumab In the second quarter of 2021, the ongoing dose escalation of COM902, our wholly owned TGT inhibitor, and following the completion of the COM902 dose escalation, the initiation of the doublet study of COM701 and COM902

12:32 in the second half of this year. With these studies in place, We are positioned to rapidly generate multiple data readouts that will be key for our development of denim axis-based new cancer immunotherapies. Our Phase 1-2 triple combination study evaluating the safety, tolerability, and preliminary anti-tumor activity of COM701 in combination with Bristol-Mers-Quibb's TGIT antibody and Nivolumab is currently enrolling patients and we expect to share initial data from the dose escalation portion of the study in the fourth quarter of this year. The purpose of this study is to allow the testing of our triple blockade hypothesis that blocking the three intersecting PVRIG, TGIT and PD-1 pathways has the potential to synergistically enhance Antitumor immune responses in selected patient populations not responsive or refractory to PD-1 blockers.

13:46 Another ongoing trial, the COM902 monotherapy dose escalation study, is an important component of COMPIGEN's overall strategy. We have seen the growing interest in TIDIT inhibitors, which now include multiple clinical stage programs, and we're closely following the developments in this space. We firmly believe it is important to pursue the development of our own candidate to maintain our control of what we believe are two key arms of the denim axis and our ability to independently evaluate multiple combination approaches which includes tidbits in the clinic.

14:35 Advancing COM902 through dose escalation and future combination studies is important for our position in the PVRIG digit space. We expect to provide initial data from the COM902 dose escalation study in the fourth quarter of this year and are on track to begin studies evaluating COM701 in combination with COM902 in the second half of this year. The preclinical data we published in Cancer Immunology and Immunotherapy strengthen our confidence in our clinical approach, providing important information on the underlying biology of STIGIT and its potential synergies with other immune checkpoints which we can leverage in our clinical strategy.

15:32 This data together with our internal PVRLG research allows us to focus and refine the indications we will pursue in the clinic to potentially maximize the probability of success of our combination strategy of COM701 and COM902. In addition, our research further demonstrates the absence of T cell depletion activity in vitro and in vivo with COM902, and therefore reinforces our COM902 approach, which was designed to have reduced ST receptor engagement to avoid potential depletion of TGIT-expressing effector T cells.

16:20 As you can see from our various scientific publications, we continue to invest in high-quality in-house research that feeds our clinical pipeline strategy in order to keep it differentiated and competitive. Our progress from target discovery, validation, and preclinical development now through to a comprehensive clinical program has been remarkable. Our discovery of the previously unknown PGRG pathway uncovered this immuno-oncology pathway, and our research and clinical work have supported our position as leaders in the Dynam-Axis space, which has been highlighted by our status as the only company with wholly owned clinical stage assets targeting both PDR-IG and TISID.

17:19 And thus, the only company currently capable of evaluating in the clinic PDR-IG monotherapy, Dual blockade of PVRIG with PD-1 or TIGIT and triple blockade of PVRIG with PD-1 and TIGIT. We're highly enthusiastic about what's to come later in the year. Most importantly, initial data from our dose escalation triple combination study. Our phase 1-2 triple combination study designed as a study in ovarian and endometrial cancers and additional tumor types with high PVRL2 expression is the ultimate test of our hypothesis and a true differentiator in the crowded immune oncology space. Beyond this exciting clinical progress, we're also continually driving forward our science which has been the foundation that underlies our clinical progress.

18:29 Our recent publications in cancer immunology immunotherapy and cancer discovery are testament to our scientific rigor and broader contributions to the fundamental biology of the genome axis. We will continue our efforts to drive the science forward Building upon our deep scientific heritage that we believe plays an integral role in our potential success. A key factor in driving our science forward involves the advancement of our early stage pipeline with multiple programs targeting the immunosuppressive tumor microenvironment, including targeting the myeloid population The expansion of our fruitful research collaboration with Johns Hopkins University to include focused research on a competent discovered novel myeloid target reinforces our ability to further discover completely new drug targets and our continued focused research and development on early stage programs.

19:47 along our clinical development execution. We are proud to continue this long-standing collaboration addressing our multiple drug candidates with Dr. Drupal Doll who played an important role in the preclinical development of COM701 and look forward to collaborating with his incredible team to advance a novel immune oncology agent that has the potential to target tumor-associated macrophages in the tumor microenvironment. We're excited by this novel myeloid target, and although this is very early days, we hope that through rigorous and deep research, we will build a strong foundation that can ultimately translate this very early-stage program to a first-in-class clinical candidate.

20:41 And while our progress Thank you very much. and our future strategic path. Investing in our early stage programs and pipeline growth engine remains high priority for Compugen and we believe in the potential of our platform to uncover additional, untapped, novel immuno-oncology targets just as we did with Adenam Axis. Finally, before turning the call over to Ari, I would like to thank the team at Compugen, our partners, investigators, shareholders, and patients. The dedication and contributions across these groups are what have enabled us to continue our on-track execution and progress despite the still ongoing COVID-19 pandemic.

22:04 We are proud to have our prior guidance for enrollment and data Thank you, Anat.

22:21 Good morning and good afternoon to everyone. Our financial results for the first quarter of 2021, released this morning, continue to reflect a solid financial position with, as expected, increased research and development expenses, due to our growing number of clinical trials. Research and development expenses for the first quarter of 2021 were $7.3 million, compared with $4.7 million for the same period in 2020. This increase is attributed mostly to CMC-related activities, specifically manufacturing costs for additional drug supply of COM701 to support the planned expansion of our various clinical trials as well as expanded clinical team located in the US which brings additional expertise to the company to ensure the successful management and execution of our ongoing and soon to be initiated clinical trials. As a reminder, our clinical expenses reflect costs associated with our expanded clinical programs which will now include COM701 in monotherapy, dual and triple combination studies, as well as load escalation study for COM902.

23:39 Net loss for the first quarter of 2021 was $9.9 million or 12 cents per basic and diluted share compared with a net loss of $7.1 million or 10 cents per basic and diluted share for the same period in 2020. As of March 31st, 2021, we had approximately $190 million in cash and cash-related accounts The company has no debt. The decrease in our cash balances of approximately $5 million net during the first quarter represent approximately $9 million of gross cash expenditures offset by a collection of $2 million from AstraZeneca related to the revenues recognized in the fourth quarter of last year, and two million dollars of working capital.

24:37 As a reminder, we expect our gross cash expenditures for 2021 to be in the range between 40 to 42 million dollars without taking into consideration any potential cash inflows for the company from existing or new collaborations. Thank you. And with that, we will now open the call for questions. Thank you. Ladies and gentlemen, at this time we will begin the question and answer session. If you have a question, please press star 1. If you wish to decline from the polling process, please press star 2. If you are using speaker equipment, kindly lift the headset before pressing the numbers. Please stand by while we poll for your questions.

25:23 The first question is from Mark Breidenbach of Oppenheimer. Please go ahead.

25:30 Hey, guys. Congrats on all the progress, and I hope everyone is staying safe on your end. Just a couple from me. First of all, should we be expecting any additional patients from either the monotherapy or nivolumab combination cohorts to be included in the analysis presented at ASCO versus what we saw in February, or will it really just be the same set with more Follow-up time. And you mentioned that there might be some correlative data presented at ASCO as well. I'm wondering if you were able to track any specific markers of DM1 activation, or will these correlative data really be more generalized indicators of immune activation and response? Yes.

26:25 So I will take the correlative assessments and let Henry relate to the clinical. On the correlative assessments, as we stated in our last quarterly call, we were able to track with very initial data, obviously, immune activation seen by COM7-1 treatment as monotherapy and also in combination with nivolumab. These data will be presented. With respect to DLM-AXIS, this is really analysis in progress, and if we show some data, it will be very, very initial. We will present the data as we will have it ready, probably in additional later conference. Henry?

27:21 Thank you. So, Mark, what we previously disclosed in February was a snapshot of the data. At ASCO, we'll present updated data, including all the patients who have been enrolled on the dose escalation arms of the study, so monotherapy dose escalation, the combination dose escalation, including follow-up. We'll also disclose data on and the patients who've been enrolled on the monotherapy expansion cohorts including follow-up on those patients also. And particularly, we will disclose data on long-term patients who have been on the study and especially the ones that we've highlighted in the prior disclosure we had in February. So, it will be a summary of all the data that's been previously disclosed and new data specifically new data in the last dose cohort of COM701 in combination with nivolumab, both at the doses of 20 milligrams per kilogram body weight dose and for 80 milligrams IVQ for weeks. So there'll be a lot more of the safety data in those cohorts.

28:33 All right. That's super helpful. Thanks for that. Just also wondering if you were able to collect any post-mortem biopsies from patients in the Phase 1 study who were on drug at the time of death, just to be able to look for any evidence of target engagement and also do a little bit of PVRL2 expression profile in any of the Phase 1 patients. Thanks for taking the questions.

29:04 Yes, as Anat mentioned in her script, there will be correlative data presented, and I'll give an opportunity to Anat to further expand on your question.

29:17 Yeah, we were collecting on the monotherapy expansion, we were collecting pre- and on-treatment. I am not sure with respect to post-mortem. I guess you'll need to wait for the – I'm not sure that we have post-mortem. for specific patients.

29:37 Okay, fair enough. All right, thanks so much for taking the questions, and we're looking forward to the ASCO presentation.

29:43 Thank you, Mark. The next question is from Stefan Willey of Stifel. Please go ahead.

29:52 Yeah, good morning. Thanks for taking the questions. Maybe just to follow up on the last question, can you – Thank you very much. The changes in CD8 till fraction that are in the tumor, you know, both pre and post treatment. So, just wondering if that's an assessment that we might see at ASCO.

30:35 So, as you correctly stated, we did speak about the blood markers and with respect to liquid biopsies, we obviously have from from the dose escalation as well as from the expansion. So here we have a little bit more. The number is a little bit higher. On the tumor biopsies, as you remember, we had 20 patients in the monotherapy expansion. Obviously, we couldn't get biopsies from all of them as paired pre and on treatment. So it's only a portion of this study. of this group and taking into consideration that in some of them obviously we didn't see a response.

31:24 So I think that the data will be limited. It's initial. The data that we have is pointing to some preliminary, as we stated, preliminary activation upon COM71 treatment. and what we're going to present will probably not be all the immunohistochemistry data because this is in progress. We will present some of the data that we have. So just to address your question, it will be limited at this point in time, but we will make sure that we present all the data when we have it probably in a later conference.

32:11 Okay, that's actually quite helpful. And then Maybe just to throw a question at you that we're getting a lot. I know that there's a competitive trial readout, I think, coming maybe later this quarter. And one of the backbone agents in that regimen that's being evaluated is an SC silent digit. So just kind of wondering, you know, what you're maybe expecting to see out of that in, I guess, you know, How do you think that data might extrapolate out to what you're pursuing with 902 right now?

32:48 Thanks. Yeah, it's a fair question that, you know, that would be the first data that is derived from an FC inactive TGC inhibitor as opposed to the rest of the data that is out there. So obviously we're looking as well to see what the data will tell us. I guess that you are well familiar and not only you Steve but also the community with our view about the need or actually the known need from our perspective as we see it based on our data on having an FC active.

33:35 We hope this will support this view that we have, which is based on data. We recently published a paper on COM902, which is further strengthening what we're saying for quite some time. We have our own COM902 clinical study. This is now in dose escalation. We promise to show data. In Q4, so obviously our data will be out there as well. So we're looking to see what the data will tell us from the other company, but also we're looking very carefully at our data as well. And we still didn't find in the public domain a reason to be concerned with our view with respect to FC Inactive Performance in Clinical Studies. So we'll see.

34:39 All right. I appreciate the answer, and congrats on the progress. Thank you. The next question is from Dana Graybosh of FZB Learing. Please go ahead.

34:55 Hi. Thank you for the question. A couple on the science side. I think we're seeing more companies talk about Targeting Tactile or CD96, the other member that you don't have a program against and sort of the DNAM access. And I wonder if the first question, and then I'll have a follow-up, but the first is, what do you think about CD96 and its role in DNAM signaling and whether you may need to target it in some patients or tumors as well?

35:28 Yeah, it's a good question. CD96 actually is a binding PVR, but it binds PVR with a lower affinity than pivot. So we think that the contribution is not really clear. Definitely PVRIG is addressing a completely different node, which is PVRIG-PVRL2. We believe that the PVRIG-PVRL2 and TGET-PVR are the two pathways that needed to be blocked in order to generate an anti-tumor activity.

36:14 I'll say that also the Whether CD96 is a positive cost-simulatory or negative cost-simulatory, that's also a question, at least in our hands and in some papers outside. So we'll see. We'll wait and see. But it doesn't change our hypothesis.

36:37 Got it. And then a follow-up on the question that Stephen just asked on the competitor data. I wonder if you can remind us how similar are – Com902 with Arcus' tidbit that's going to have the data. Any notable differences in addition to the similarity that we should consider when looking at that data?

37:01 So, first with respect, our antibody is ITG4. I believe there is this ITG1 mutated, but still ST inactive. And in general, our antibody is an ultra-high affinity antibody. That's an antibody that we've developed from day one to be complementary with COM701. And we tested it also benchmarked to other 2D antibodies. We don't have a reason to believe that epitopes would play a role here, different epitopes, like, you know, similarly to PD-1.

37:50 But generally, the difference is the ultra-high affinity with respect to our antibody. So we'll see.

37:58 Thank you very much. Thank you. The next question is from Ren Benjamin of JMP Securities. Please go ahead.

38:08 Hey, good morning, guys. Thanks for taking the questions. Anat, you mentioned the additional data in the fourth quarter of this year. Can you give us a sense as to how many patients' worth of data we might be seeing for both studies, and would it be enough to make some reasonable conclusions about a path? and others.

38:34 Henry, would you like to address this question?

38:38 Sure. So the two, Ren, so the two key projected data that will be anticipated will be for the treated antibody like Anat mentioned, COM902. So for that, as you know, Reni, it is, It's a design that has an accelerated portion to it. So we have single-scale subject patient cohorts and also we have a three plus three subject dose level cohort. I cannot project for you now the total number of patients that we will expect to see, but certainly it will be at least more than four patients that will enroll because we'll go past the single subject dose level cohorts.

39:25 We're continuing to accumulate data on that study. So maybe at another presentation we'll be able to hone in more on the absolute number of patients that were projected. Okay? Got it. And then the triple combination? Yes. So for the triple combination, we also have that ongoing. It's a three plus three study design also. The projection when we started that, this escalation study, is to go as high as 20 mg per kg body weight dose with COM701 in combination with the other two agents. So the other two agents are the BMS-986207, the BMS-TGIT antibody, and nivolumab.

40:16 So far, as we keep on, we're on track. At a later teleconference, we'll be able to tell you how many patients we expect But certainly, the reason we are projecting that we'll get up to 20 milligrams per kilogram body weight dose of COM701 in combination with the other two agents is because, as you remember, the dose that we've recommended for expansion for COM701 is the 20 milligrams per kilogram body weight dose IVQ four weeks. As we go along, we'll be able to further refine how many patients that will present at that time. Got it.

41:01 Okay. And then just, you know, regarding the biomarker data that you'll be disclosing at ASCO as well as, you know, later on in the year, it seems to me that ultimately the You are probably in search of a patient signature or some sort of signature that might allow you to identify patients that would respond to either 701 or a combination of 701 and 902. Am I thinking about that correctly, that ultimately all these analyses will help you to identify the patients better? Are you looking at these data more to boost the current clinical benefit rates that you're seeing to more of objective responses?

41:59 Or do you kind of feel that SBs right now are pretty good and if you can get more people with stable diseases, that would be just fine?

42:10 Actually both and also for better understanding the mechanism of action of COM701 treatment. The biomarker strategy is broad enough in order to address tumor biopsies and also information gathered from Blood samples, we have the component of the retrospective analysis, and you also know that we have the component of patient selection. Basket studying, the triplet. We are looking to understand what the tumors are telling us following Com7-1 treatment, monotherapy or combination, and whatever we can get to better understand what's going on in patients.

43:00 in tumor macroenvironment remodeling, et cetera. So both goals that you mentioned, but also better understand the mechanism of action.

43:10 Got it. I guess just one final question for me. I'd love to just kind of get your thoughts on the TIGIT landscape as you see it right now, how it's unfolded with the data that we've seen to date, and kind of, you know, how – might be able to sort of thread the needle in the space.

43:33 I'll let Henry address it, but I'll just say that, you know, currently the studies are ongoing. Of course, the different indications are mostly PD-L1 high. As we stated for quite some time, we believe that PVRIG will be complementary, and you can see that our clinical strategy is is addressing more the PD-L1 low and non-responsive patient population. With our digits, obviously, the key differentiating factor is the fact that we can combine it with COM701. But I'd like Henry to address more the landscape and our strategy with COM702.

44:21 Yeah, thank you, Anat. So really, I think what's key here is that this provides opportunities for better treatment options for patients who have advanced disease. Most of the data that's been presented prior to the release by Roe, Steen and Teck was just escalation by Uncle Med Mario. Now we have more data from Roe, Steen and Teck. and like Anat alluded to, this is more robust data because it's a randomized study in non-small cell lung cancer and it appears that the activity of the combination of vertigate plus the PD-L1 inhibitor is better enhanced in patients who have high PD-L1 expression.

45:14 The data from Merck also shows that the combination appears better in combination, better results in combination with a PD-1 inhibitor. So that's good for patients. What is currently unknown at this time, I don't think personally speaking as an oncologist and looking at all the data that's been there is whether there will be an impact with the kind of SC that one has We're looking forward to data disclosures by ARCAs as they've iterated that they will have an interim analysis of their data. But we believe, like Anat has mentioned, that COM902 will have anti-tumor activity and that it will appear blocker that it will probably show based on the science that there should be no difference in terms of whether there is an FC-enhanced or non-FC-enhanced.

46:20 However, this data are all that we're collecting are all ongoing, and we'll see what ARCOS presents also. I'd just like to add that Anat, I completely align with what Anat has said, that what actually differentiates CompuGen is that we are going to be testing a PD-1 and a PD-L1-free regimen. where it will be the combination of COM902 with COM701 and we'll see what the preliminary safety, tolerability, and anti-tumor activity of the combination will be. But also remember that we have a triple combination study that's ongoing in collaboration with DMS, obviously, where we're testing the DNAM hypothesis of complete inhibition of the various aspects of the DNAM access.

47:16 So it's all incredible and exciting data that we hope to see over the next several months and before the end of the year. And hopefully this will all lead to a clinical benefit for patients who are desperately in need of better treatment options.

47:35 Perfect. Thanks very much for taking the questions. The next question is from Astika Kundwandini of Tooth Securities. Please go ahead.

47:48 Hi, guys. Thanks for taking my questions. I want to revisit something here. On the triple, can you tell me what dose level of COM701 that you will begin de-escalation? I just want to clarify, are you starting that at a dose with COM701 dose at 20 mgs per kg or something like that? maybe around that area. And then I have another question. On the more complete IHC data that you alluded that you'll follow up with at a later conference, will that be something the second half of 2021 as well that we can expect? Thanks so much.

48:30 So I'll start with the IHC, and then Henry will take the triplet dose escalation question. We did not share guidance, but as I said, this is in progress. Hopefully we can still present it this year, but we will give specific guidance when we know more.

48:55 Okay. All right, thank you, Anat. So, I think with regards to the triplet combination, what we've disclosed is that we'll have approximately up to five dose level sequential dose escalation cohorts in combination with six doses of the BMS digit antibody 98607 and nivolumab. So, inherently, that means that we will not be starting at 20 milligrams per kilogram body weight dose of COM701 in combination with the other two agents.

49:29 Got it. Thanks, guys. The next question is from Roger Song of Jefferies. Please go ahead.

49:39 Great. Yeah, congrats on the progress. And most of my questions related to 701 and 902 has been raised and answered, so I won't repeat. Maybe just a quick question related to that John Hopkins collaboration. So we know the myeloid target is one of the pillar of your computational discovery platform. Maybe could you just provide some additional colors in terms of the nature of the collaboration and then maybe more specifically, what are the steps in the timeline for the candidate nomination and the potential kind of R&D?

50:21 Yes, sure, as much as we can relate to it, we didn't disclose much, but I'll just say that the collaboration with Hopkins is very similar to how we conducted the collaboration for a few years now. Hopkins is part of executing the research on the candidates, as I stated earlier. There were also parts on some of the preclinical work on COM701. So this is the nature of the collaboration. Specifically for this myeloid target, this is a very early stage one. It still merits research in order to explore the therapeutic potentials.

51:08 We believe it's exciting and as we disclosed, we have seen some tumor growth inhibition in genetic depletion animal models. The mechanism seems interesting, but it requires a lot of research. and this is why we thought that it would be good to go hand in hand with the laboratory of Drupal Doll and his excellent team that were used to work with them and do the work together. That's what I can say about this specific direct target.

51:56 Great. Thanks for the color. Yeah, I won't leave Ari out of this conversation. Maybe Ari, I believe you provide some kind of color around the OpEx and cash. Maybe just remind us, what is the current guidance around the cash run way?

52:13 Hey, Roger Shul. So, we ended the quarter with about $190 million. As we stated before, the yearly run rate for the yearly Venn rate expenditures would be roughly between $40 to $42 million. So, having said that, assuming we will not increase significantly the cash Venn rate, We're talking about at least cash sufficient through the end of 2023. Having said that, again, if we do decide based on our clinical strategy to expand and to increase the clinical trials, obviously this estimation might change.

52:52 Great. Thank you. That's all from me. Congrats again.

52:56 Thank you. The next question is from Tony Butler of Ross Capital. Please go ahead.

53:04 Yes, thanks very much. Appreciate you working me in here. Question, Anat and Henry, is around 701 and 902, the combination trial. Henry, you alluded to the fact that for safety reasons, you would want to see that combination, but don't you actually get that with the triple? And I guess outside of dosing, that is the amount that you would use optimally with 701 with the optimal dose for 902. What else might you actually define, if anything, for eliminating both co-inhibitors in the DNA maxis in the absence of a PD-1 antibody?

53:50 Tony, thank you for your question. Remember that in the process of doing a dose escalation study, The intent is to evaluate what the safety and tolerability of that combination that you're testing. So if you have three study drugs that you're combining as part of a dose escalation, it is impossible to be able to extricate what the contribution to safety of either one of the components or two of the components are. You can only speak to what that combination does in terms of safety and tolerability, especially within the DLT window that you've assigned for the course of the dose escalation and also intermediate and long-term toxicities, right? Now, for the dual, so therefore, it will not be possible to allude completely to what a TGIT inhibitor does separately as part of a triple combination.

55:00 And also remember that even though we get some data from what the combination of a TGIT inhibitor does as part of that triplet combination of COM701, Rivolumab, it's a different TGIT antibody. So the TGIT antibody that we're using in the triplet combination is the TGIT antibody from BMS 986207. It cannot separate entity itself. So it cannot transfer the safety and tolerability of one antibody to the other. You can get an idea of what the relative toxicity is, but you cannot transpose it to another antibody.

55:46 So therefore, there is a need Since the two agents I will be combining, which are ours, COM701, we know the safety and tolerability of COM701. As you remember, Tony, we started at 0.01 milligrams per kilogram body weight dose, and we've dose escalated through 20 milligrams per kilogram body weight dose IDQ for weeks. So we have a lot of data on COM701. It's an unapproved agent. So it's an antibody that we're still collecting data on, but we're relatively comfortable with what we see in terms of its preliminary anti-tumor activity and safety and tolerability. COM902 is another new agent. It's a ticket antibody.

56:36 But remember that it has never been combined with COM701, which is another unapproved. So we have two unapproved agents. And as far as the regulations go and clinical practice and conducting clinical trials, you have to be able to compile the safety information of those two agents separately without any other agents in combination. So it just will be dual combination. The expectation is, because we know what the safety profile of COM701 is, very well tolerated, we do not expect to see anything that is out of the blue when we combine with COM902.

57:21 But at any rate, that's why we're doing the clinical study. So even though the triplet will inform a little bit, it will still not be sufficient. to fulfill regulatory obligations with a combination of COM 701 and COM 902. I hope that answers your question.

57:42 It does, Henry, and thank you for the clarity. And please understand, part of the rationale was, would you find other information outside of safety? But I think you've made it very, very clear what the goal is, and I appreciate it. This concludes our Q&A session. I will now turn the call back to Compugen's President and CEO, Dr. Han Dayan. Would you like to make your concluding statements?

58:12 Yes, thank you. Thank you all for joining the call today. 2021 is poised to be an important year for Compugen, with meaningful milestones and multiple data readouts. Thank you for joining us today and your continued support. Stay safe and healthy. Thank you. This concludes the Compugens Limited webinar. First Quarter 2021 Financial Result Conference Call.

58:57 Thank you for your participation. You may go ahead and disconnect.

Follow Compugen Ltd. into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Dr. Anat Cohen-Dayag

President and CEO

Ari Krashen

Chief Financial Officer and Chief Operating Officer

Dr. Henry Attaway

Chief Medical Officer

Mark Breidenbach

Analyst, Oppenheimer & Co.

Stefan Willey

Analyst, Stifel

Dana Graybosh

Analyst, FZB Learing

Ren Benjamin

Analyst, JMP Securities

Astika Kundwandini

Analyst, Tooth Securities

Roger Song

Analyst, Jefferies

Tony Butler

Analyst, Ross Capital

More from Compugen Ltd.